AB Technology announces data from advancement program of masitinib in GIST AB Technology SA.

AB Technology announces data from advancement program of masitinib in GIST AB Technology SA , a pharmaceutical company focusing on the extensive research, development and commercialization of protein kinase inhibitors , announces today that data from the development system of masitinib in gastrointestinal stromal tumors have been presented as part of three presentations delivered at the American Culture of Clinical Oncology 2012 Annual Meeting, june in Chicago 1-5, Illinois.In May, at that time the Berkeley breakthrough was reported, experts writing in the journal Nature Chemical Biology offered up guidelines on safeguarding yeast-based opioid production from criminals. According to an organization led by Kenneth Oye, director of plan and practices at the Synthetic Biology Engineering Research Center at Massachusetts Institute of Technology in Boston, individuals safeguards should include four key points: Engineer the yeast strains to create them less attractive to criminals. They could be designed to produce only opiates with limited road value. Or, they could be made to be so hard to process that it’s not worth the effort.